Literature DB >> 27371673

Association of Plasma DPP4 Activity With Mild Cognitive Impairment in Elderly Patients With Type 2 Diabetes: Results From the GDMD Study in China.

Tianpeng Zheng1, Linyuan Qin2, Bo Chen3, Xueping Hu4, Xiaoxi Zhang5, Yihong Liu6, Hongbo Liu7, Shenghua Qin8, Gang Li9, Qinghua Li10.   

Abstract

OBJECTIVE: Hyperglycemia, inflammation, and oxidative stress are thought to be involved in the pathogenesis of cognitive decline. Dipeptidyl peptidase-4 (DPP4) is a newly identified adipokine related to these risk factors. Hence, we aimed to investigate the association between plasma DPP4 activities and mild cognitive impairment (MCI) in elderly patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: We evaluated plasma DPP4 activity, inflammatory markers, and oxidative stress parameters in a cross-sectional sample of 1,160 patients with type 2 diabetes aged 60 years or older in China. MCI was diagnosed based on criteria established by the National Institute on Aging-Alzheimer's Association workgroups
RESULTS: Patients in the highest quartile of DPP4 activity had higher HbA1c, interleukin 6 (IL-6), CRP, nitrotyrosine, 8-iso-PGF2a, and lower Montreal Cognitive Assessment (MoCA) scores compared with subjects in the lowest quartile (P < 0.001). In the highest DPP4 quartile, MCI risk was higher (odds ratio 3.49; 95% CI 1.97-4.57) than in the lowest quartile after adjustment for potential confounders. The risk for MCI increased more with higher levels of DPP4 activity, IL-6, CRP, nitrotyrosine, and 8-iso-PGF2a (P < 0.05), but not with higher levels of HbA1c.
CONCLUSIONS: This study shows that increased DPP4 activities are independently associated with MCI in elderly patients with type 2 diabetes. The mechanisms might be partly explained by the effect of DPP4 on inflammation and oxidative stress. These observations raise further interest in DPP4 activity for its potential effect on these MCI-related risk factors as a biological marker or even a possible therapeutic target for MCI.
© 2016 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27371673     DOI: 10.2337/dc16-0316

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  16 in total

1.  Vildagliptin, a DPP4 inhibitor, alleviates diabetes-associated cognitive deficits by decreasing the levels of apoptosis-related proteins in the rat hippocampus.

Authors:  Dan-Dan Zhang; Nan Shi; Hui Fang; Liang Ma; Wei-Ping Wu; Ya-Zhong Zhang; Jin-Li Tian; Luo-Bing Tian; Kang Kang; Si Chen
Journal:  Exp Ther Med       Date:  2018-04-02       Impact factor: 2.447

Review 2.  Neurobiological Highlights of Cognitive Impairment in Psychiatric Disorders.

Authors:  Anna Morozova; Yana Zorkina; Olga Abramova; Olga Pavlova; Konstantin Pavlov; Kristina Soloveva; Maria Volkova; Polina Alekseeva; Alisa Andryshchenko; Georgiy Kostyuk; Olga Gurina; Vladimir Chekhonin
Journal:  Int J Mol Sci       Date:  2022-01-22       Impact factor: 5.923

3.  Vildagliptin Has a Neutral Association With Dementia Risk in Type 2 Diabetes Patients.

Authors:  Chin-Hsiao Tseng
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-30       Impact factor: 5.555

4.  Strong Association between Plasma Dipeptidyl Peptidase-4 Activity and Impaired Cognitive Function in Elderly Population with Normal Glucose Tolerance.

Authors:  Bo Chen; Tianpeng Zheng; Linyuan Qin; Xueping Hu; Xiaoxi Zhang; Yihong Liu; Hongbo Liu; Shenghua Qin; Gang Li; Qinghua Li
Journal:  Front Aging Neurosci       Date:  2017-07-26       Impact factor: 5.750

5.  Mild Cognitive Impairment in Young Type 1 Diabetes Mellitus Patients and Correlation with Diabetes Control, Lipid Profile, and High-sensitivity C-reactive Protein.

Authors:  Naveen Kumar; Veer B Singh; Babu L Meena; Deepak Kumar; Harish Kumar; Makhan Lal Saini; Arun Tiwari
Journal:  Indian J Endocrinol Metab       Date:  2018 Nov-Dec

6.  SOMAscan-based proteomic measurements of plasma brain natriuretic peptide are decreased in mild cognitive impairment and in Alzheimer's dementia patients.

Authors:  Edin Begic; Suncica Hadzidedic; Ajla Kulaglic; Belma Ramic-Brkic; Zijo Begic; Mirsada Causevic
Journal:  PLoS One       Date:  2019-02-14       Impact factor: 3.240

7.  Mild cognitive decline in type 2 diabetes mellitus patients - risk factors and pathogenesis: role of DPP4 activity and future possible therapeutic targets.

Authors:  Owais Gul; Saqib Gul
Journal:  Neuropsychiatr Dis Treat       Date:  2019-02-04       Impact factor: 2.570

8.  Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus.

Authors:  Geert Jan Biessels; Jolien Janssen; Esther van den Berg; Bernard Zinman; Mark A Espeland; Michaela Mattheus; Odd Erik Johansen
Journal:  BMC Neurol       Date:  2018-01-15       Impact factor: 2.474

9.  Triglyceride-mediated influence of serum angiopoietin-like protein 8 on subclinical atherosclerosis in type 2 diabetic patients: results from the GDMD study in China.

Authors:  Tianpeng Zheng; Bo Ge; Hongbo Liu; Bo Chen; Linyuan Qin; Liuping Xiao; Jianfei Song
Journal:  Cardiovasc Diabetol       Date:  2018-07-15       Impact factor: 9.951

10.  Renoprotective Effect of a Dipeptidyl Peptidase-4 Inhibitor on Aging Mice.

Authors:  Tae H Ban; Eun N Kim; Min Y Kim; Ji H Lim; Jong H Lee; Hyung D Kim; Hye E Yoon; Cheol W Park; Bum S Choi
Journal:  Aging Dis       Date:  2020-05-09       Impact factor: 6.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.